Beigene Switzerland GmbH has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Scientists at Beigene Ltd. and Beigene Switzerland GmbH have divulged serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of inflammatory and autoimmune diseases.

Scientists at Beigene Ltd. and Beigene Switzerland GmbH have identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA related overgrowth spectrum (PROS).

Beigene Switzerland GmbH has disclosed pyrrolobenzodiazepine (PBD) compounds and antibody-drug conjugates comprising PBDs.

Beigene Switzerland GmbH has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Scientists at Beigene Ltd. and Beigene Switzerland GmbH have disclosed antibody-drug conjugates comprising a carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) binding antibody or antigen binding fragments linked to a cytotoxic drug through a linker.